Brivanib BMS540215 (also known as BMS-540215 or Brivanib alaninate) is a chemical compound that is used in scientific research as an inhibitor of vascular endothelial growth factor receptors (VEGFRs) and fibroblast growth factor receptors (FGFRs). This inhibition has potential applications in treating certain medical conditions related to abnormal cell growth, such as cancer.
Chemical name: The chemical name of Brivanib BMS540215 is N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazolin-4-amine.
Molecular formula: The molecular formula of Brivanib BMS540215 is C19H20BrFN4O2.
Formula weight: The molecular weight of Brivanib BMS540215 is 422.29 g/mol.
CAS No: The CAS number of Brivanib BMS540215 is 649735-46-6.
Top ten keywords from Google and Synonyms:
Synonyms: • BMS-540215 • Brivanib alaninate • N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazolin-4-amine • Dual VEGFR/FGFR inhibitor BMS540215
Health benefits of this product: Brivanib BMS540215 inhibits the activity of both vascular endothelial growth factor receptors (VEGFRs) and fibroblast growth factor receptors (FGFRs), which play a role in various cellular processes like cell proliferation, differentiation, migration, and survival. By inhibiting VEGFRs and FGFRs, Brivanib BMS540215 can potentially affect these processes, leading to changes in cell behavior, including cell cycle arrest or apoptosis. This inhibition has potential applications in treating certain medical conditions related to abnormal cell growth, such as cancer.
Potential effects: Brivanib BMS540215 inhibits the activity of both vascular endothelial growth factor receptors (VEGFRs) and fibroblast growth factor receptors (FGFRs), which play a role in various cellular processes like cell proliferation, differentiation, migration, and survival. By inhibiting VEGFRs and FGFRs, Brivanib BMS540215 can potentially affect these processes, leading to changes in cell behavior, including cell cycle arrest or apoptosis. This inhibition has potential applications in treating certain medical conditions related to abnormal cell growth, such as cancer.
Product mechanism: Brivanib BMS540215 inhibits the activity of both vascular endothelial growth factor receptors (VEGFRs) and fibroblast growth factor receptors (FGFRs) by binding to the ATP-binding site of these enzymes. VEGFRs and FGFRs are involved in various cellular processes, including cell proliferation, differentiation, migration, and survival. By inhibiting VEGFRs and FGFRs, Brivanib BMS540215 can block these processes and potentially reduce abnormal cell growth.
Safety: Brivanib BMS540215 is mainly used in scientific research and has not been approved for human use. Its safety in humans is not well established, and there may be potential side effects associated with its use. Individuals should seek advice from a healthcare professional before using Brivanib BMS540215.
Side effects: The potential side effects of Brivanib BMS540215 are not well-established as it is primarily used in scientific research. However, there may be potential risks associated with its use, including toxicity and effects on normal cell growth.
Dosing information: Brivanib BMS540215 is mainly used in scientific research and dosing information is determined based on the specific experiment being performed. Individuals should consult with a qualified scientist or healthcare professional for guidance on appropriate dosing.
Conclusion: Brivanib BMS540215 is a chemical compound that is commonly used in scientific research as an inhibitor of both vascular endothelial growth factor receptors (VEGFRs) and fibroblast growth factor receptors (FGFRs). The inhibition of VEGFRs and FGFRs has potential applications in treating certain medical conditions related to abnormal cell growth, such as cancer. Although mainly used in scientific research, potential side effects and safety concerns should be taken into consideration if considering its use. Further studies are needed to determine the safety and efficacy of Brivanib BMS
